Glenmark Pharma Share Price Jumps 10% After AbbVie Deal | Stock Hits Record High

📈 Glenmark Pharma Share Price Hits Record High After $700 Million AbbVie Oncology Deal

Mumbai, July 11, 2025 — The Glenmark Pharma share price surged to a new all-time high of ₹2,094 apiece on Friday, after the drugmaker announced a high-value global licensing deal with AbbVie, focused on its subsidiary’s novel oncology pipeline.

Shares were locked in the 10% upper circuit, signalling strong investor enthusiasm following the announcement. With this move, Glenmark becomes one of the top gainers in the Nifty Pharma index, drawing renewed interest from institutional and retail investors alike.

🔑 Strategic Overview: Glenmark’s Oncology Bet Gains Global Momentum

Under the agreement, Ichnos Glenmark Innovation (IGI), a U.S.-based innovation arm of Glenmark, will license out its investigational cancer drug ISB 2001 to AbbVie for development and commercialisation in key developed markets.

Deal terms include:

• ✅ $700 million upfront payment (subject to regulatory approvals)
• ✅ Up to $1.225 billion in milestone-linked payouts
• ✅ Double-digit royalties on net global sales
• ✅ Territory split: AbbVie takes North America, EU, Japan, and Greater China; Glenmark retains emerging markets including Asia (ex-Japan/China), Latin America, CIS, and MENA

Also Read : Crizac Share Price Today: Stock Gains 9% After 14.7% Premium Listing

🔬 About ISB 2001: A Targeted Cancer Therapy

Glenmark’s latest collaboration with AbbVie marks a pivotal advancement in its specialty pharma journey, centered on its investigational cancer molecule, ISB 2001. This novel asset is a trispecific T-cell engager, engineered to simultaneously target BCMA and CD38 antigens on multiple myeloma cells, while activating CD3 receptors on T-cells, thereby enhancing immune-mediated tumor cell destruction. The molecule is in Phase 1 trials and is being studied for relapsed or refractory multiple myeloma.

This marks one of the few high-value biopharmaceutical licensing deals by an Indian drugmaker in recent times, reinforcing Glenmark’s transition toward specialty and biologic drugs.

📊 Glenmark Pharma Share Price: Performance & Outlook

The rally comes after a strong Q1 performance, where Glenmark posted a modest turnaround in profitability and improved operational efficiency.

📉 Glenmark’s recent partnership with AbbVie represents a significant milestone in its shift toward specialty pharmaceuticals, anchored by its experimental oncology asset, ISB 2001.

🔎 Why This Matters for Investors

This development positions Glenmark as a credible player in the immuno-oncology space — a segment expected to see exponential growth. It also provides:

• 🔄 Revenue diversification through high-margin assets
• 🌐 Stronger global footprint via AbbVie’s commercial expertise
• 📦 Non-dilutive capital infusion that may reduce Glenmark’s debt burden

However, investors should remain mindful of the clinical and regulatory risks inherent to early-stage oncology drug development.

📢 Conclusion: Is the Rally Sustainable?

While the Glenmark Pharma share price has seen a sharp re-rating post the AbbVie partnership, the future trajectory depends on drug development milestones and the company’s ability to deliver on R&D-led growth. The deal marks a strategic pivot, but valuation comfort may hinge on progress updates from ISB 2001’s clinical trials.

Retail investors are advised to monitor further disclosures, while long-term investors may see this as Glenmark’s entry point into the global biologics arena.